Rare diseases
![Alnylam gives up on Onpattroās US expansion after FDA rejects its rare heart disease indication](https://pharmtales.com/wp-content/uploads/2023/10/Onpattros-US-bid-for-rare-heart-disease-fails.jpg)
Alnylam gives up on Onpattroās US expansion after FDA rejects its rare heart disease indication
Despite receiving an endorsement from an advisory committee, the FDA has reached a different conclusion regarding the benefit-risk profile of ...
![Amgen Successfully Completes $27.8B Acquisition of Horizon After FTC Dispute Resolution](https://pharmtales.com/wp-content/uploads/2023/10/Amgen-Successfully-Completes-27.8B-Acquisition-of-Horizon-After-FTC-Dispute-Resolution.jpg)
Amgen Successfully Completes $27.8B Acquisition of Horizon After FTC Dispute Resolution
Amgen has successfully concluded its monumental $27.8 billion acquisition of Horizon Therapeutics, triumphing over a legal challenge posed by the ...
![Novartisā iptacopan impresses in phase 3 trial for rare kidney disease](https://pharmtales.com/wp-content/uploads/2023/10/Novartis-iptacopan-impresses-in-phase-3-trial-for-rare-kidney-disease.jpg)
Novartisā iptacopan impresses in phase 3 trial for rare kidney disease
Novartis is celebrating a significant achievement as its investigational oral factor B inhibitor reaches a crucial milestone in a phase ...
![Ionisā olezarsen slashes triglycerides and pancreatitis in rare disease patients](https://pharmtales.com/wp-content/uploads/2023/09/Ionis-olezarsen-slashes-triglycerides-and-pancreatitis-in-rare-disease-patients.jpg)
Ionisā olezarsen slashes triglycerides and pancreatitis in rare disease patients
Ionis Pharmaceuticals has achieved a significant milestone in its phase 3 clinical trial for lipid-lowering therapy, bringing the company closer ...
![filspari confirmatory trial results, travere filspari fda approval status, filspari igan drug, filspari kidney function endpoint, travere filspari phase 3 trial, filspari proteinuria reduction, filspari safety and efficacy igan](https://pharmtales.com/wp-content/uploads/2023/09/Filspari-fails-to-confirm-kidney-benefit-in-IgAN-but-Travere-hopes-to-keep-FDA-approval.jpg)
Filspari fails to confirm kidney benefit in IgAN, but Travere hopes to keep FDA approval
Half a year after securing accelerated approval for the treatment of a rare kidney ailment, Travere Therapeuticsā groundbreaking drug, Filspari, ...
![Clinigen, advocacy groups, rare diseases, NaviGATE program, Association of the British Pharmaceutical Industry](https://pharmtales.com/wp-content/uploads/2023/09/Clinigen-launches-initiative-to-bridge-the-gap-between-rare-disease-communities-and-pharma.jpg)
Clinigen launches initiative to bridge the gap between rare disease communities and pharma
Clinigen, a pharmaceutical services company based in the UK, is launching the NaviGATE initiative to empower patient advocacy groups within ...
![AstraZeneca and Verge partner to discover AI-driven drugs for rare neurodegenerative diseases](https://pharmtales.com/wp-content/uploads/2023/09/AstraZeneca-and-Verge-partner-to-discover-AI-driven-drugs-for-rare-neurodegenerative-diseases-1.jpg)
AstraZeneca and Verge partner to discover AI-driven drugs for rare neurodegenerative diseases
Verge Genomics is expanding its roster of Big Pharma partnerships by teaming up with AstraZeneca in a substantial $42 million ...
![Ipsen, Clementia, FDA, Roche, Pharma, rare diseases, FDA approval, Sohonos](https://pharmtales.com/wp-content/uploads/2023/08/FDA-Grants-Approval-to-Ipsens-Sohonos-Capsules-the-First-Ever-Treatment-for-Individuals-with-Fibrodysplasia-Ossificans-Progressiva.jpg)
FDA Grants Approval to Ipsen’s Sohonos Capsules, the First-Ever Treatment for Individuals with Fibrodysplasia Ossificans Progressiva
In 2019, Ipsen made a significant investment of $1 billion to acquire Clementia Pharmaceuticals and its rare disease drug, palovarotene. ...